Adenosine receptor antagonists and retinal neovascularization in vivo

Robert P. Mino, Polyxenie E. Spoerri, Sergio Caballero, Denifleld Player, Luiz Belardinelli, Italo Biaggioni, Maria B. Grant

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

PURPOSE. The role of adenosine receptor (AdoR) antagonists in human retinal endothelial cell function in vitro has previously been determined. In this study, efficacy of AdoR antagonist administration in reducing retinal neovascularization was examined in a mouse pup model of oxygen-induced retinopathy. METHODS. A previously described model of oxygen-induced retinal neovascularization in newborn mouse pups was used to examine the effect of various AdoR antagonists on neovascularization. The nonselective AdoR antagonist xanthine amine congener (XAC), the A 2A-selective antagonist ZM241385, the A 2B-selective antagonists 3-N-propylxanthine (enprofylline) and 3-isobutyl-8-pyrrolidinoxanthine (IPDX), and the A 1-selective antagonist cyclopentyl-1,3-dipropylxanthine (CPX) were used. After the hyperoxia exposure the animals received daily intraperitoneal injections of pharmacologically relevant doses of AdoR antagonists for 5 days. Control animals received vehicle (0.1% dimethyl sulfoxide [DMSO]) alone. The animals were then killed and perfused with fluorescein-dextran. Whole-mounts of retinas from one eye were prepared and examined, whereas the retinas of the contralateral eye were embedded, sectioned, and stained for counting neovascular nuclei extending beyond the internal limiting membrane into the vitreous. RESULTS. Angiography of wholemount retinas showed reduction of neovascular tufts in animals treated with selective A 2B AdoR antagonists. Quantification of the extraretinal neovascular nuclei showed that only animals treated with XAC, enprofylline, or IPDX showed a significant reduction in retinal neovascularization. By contrast, neither CPX nor ZM241385 had an effect on neovascularization. CONCLUSIONS. The A 2B-seIective AdoR antagonists inhibited oxygen-induced retinal neovascularization in vivo and may provide a basic for developing pharmacologic therapies for the treatment of proliferative retinonathies.

Original languageEnglish (US)
Pages (from-to)3320-3324
Number of pages5
JournalInvestigative Ophthalmology and Visual Science
Volume42
Issue number13
StatePublished - 2001
Externally publishedYes

Fingerprint

Retinal Neovascularization
Purinergic P1 Receptor Antagonists
Retina
Xanthine
Oxygen
Amines
Hyperoxia
Dimethyl Sulfoxide
Intraperitoneal Injections
Angiography
Endothelial Cells
Membranes
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Mino, R. P., Spoerri, P. E., Caballero, S., Player, D., Belardinelli, L., Biaggioni, I., & Grant, M. B. (2001). Adenosine receptor antagonists and retinal neovascularization in vivo. Investigative Ophthalmology and Visual Science, 42(13), 3320-3324.

Adenosine receptor antagonists and retinal neovascularization in vivo. / Mino, Robert P.; Spoerri, Polyxenie E.; Caballero, Sergio; Player, Denifleld; Belardinelli, Luiz; Biaggioni, Italo; Grant, Maria B.

In: Investigative Ophthalmology and Visual Science, Vol. 42, No. 13, 2001, p. 3320-3324.

Research output: Contribution to journalArticle

Mino, RP, Spoerri, PE, Caballero, S, Player, D, Belardinelli, L, Biaggioni, I & Grant, MB 2001, 'Adenosine receptor antagonists and retinal neovascularization in vivo', Investigative Ophthalmology and Visual Science, vol. 42, no. 13, pp. 3320-3324.
Mino RP, Spoerri PE, Caballero S, Player D, Belardinelli L, Biaggioni I et al. Adenosine receptor antagonists and retinal neovascularization in vivo. Investigative Ophthalmology and Visual Science. 2001;42(13):3320-3324.
Mino, Robert P. ; Spoerri, Polyxenie E. ; Caballero, Sergio ; Player, Denifleld ; Belardinelli, Luiz ; Biaggioni, Italo ; Grant, Maria B. / Adenosine receptor antagonists and retinal neovascularization in vivo. In: Investigative Ophthalmology and Visual Science. 2001 ; Vol. 42, No. 13. pp. 3320-3324.
@article{b1d74fd8594a4e54bdc5eb45e67bef32,
title = "Adenosine receptor antagonists and retinal neovascularization in vivo",
abstract = "PURPOSE. The role of adenosine receptor (AdoR) antagonists in human retinal endothelial cell function in vitro has previously been determined. In this study, efficacy of AdoR antagonist administration in reducing retinal neovascularization was examined in a mouse pup model of oxygen-induced retinopathy. METHODS. A previously described model of oxygen-induced retinal neovascularization in newborn mouse pups was used to examine the effect of various AdoR antagonists on neovascularization. The nonselective AdoR antagonist xanthine amine congener (XAC), the A 2A-selective antagonist ZM241385, the A 2B-selective antagonists 3-N-propylxanthine (enprofylline) and 3-isobutyl-8-pyrrolidinoxanthine (IPDX), and the A 1-selective antagonist cyclopentyl-1,3-dipropylxanthine (CPX) were used. After the hyperoxia exposure the animals received daily intraperitoneal injections of pharmacologically relevant doses of AdoR antagonists for 5 days. Control animals received vehicle (0.1{\%} dimethyl sulfoxide [DMSO]) alone. The animals were then killed and perfused with fluorescein-dextran. Whole-mounts of retinas from one eye were prepared and examined, whereas the retinas of the contralateral eye were embedded, sectioned, and stained for counting neovascular nuclei extending beyond the internal limiting membrane into the vitreous. RESULTS. Angiography of wholemount retinas showed reduction of neovascular tufts in animals treated with selective A 2B AdoR antagonists. Quantification of the extraretinal neovascular nuclei showed that only animals treated with XAC, enprofylline, or IPDX showed a significant reduction in retinal neovascularization. By contrast, neither CPX nor ZM241385 had an effect on neovascularization. CONCLUSIONS. The A 2B-seIective AdoR antagonists inhibited oxygen-induced retinal neovascularization in vivo and may provide a basic for developing pharmacologic therapies for the treatment of proliferative retinonathies.",
author = "Mino, {Robert P.} and Spoerri, {Polyxenie E.} and Sergio Caballero and Denifleld Player and Luiz Belardinelli and Italo Biaggioni and Grant, {Maria B.}",
year = "2001",
language = "English (US)",
volume = "42",
pages = "3320--3324",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "13",

}

TY - JOUR

T1 - Adenosine receptor antagonists and retinal neovascularization in vivo

AU - Mino, Robert P.

AU - Spoerri, Polyxenie E.

AU - Caballero, Sergio

AU - Player, Denifleld

AU - Belardinelli, Luiz

AU - Biaggioni, Italo

AU - Grant, Maria B.

PY - 2001

Y1 - 2001

N2 - PURPOSE. The role of adenosine receptor (AdoR) antagonists in human retinal endothelial cell function in vitro has previously been determined. In this study, efficacy of AdoR antagonist administration in reducing retinal neovascularization was examined in a mouse pup model of oxygen-induced retinopathy. METHODS. A previously described model of oxygen-induced retinal neovascularization in newborn mouse pups was used to examine the effect of various AdoR antagonists on neovascularization. The nonselective AdoR antagonist xanthine amine congener (XAC), the A 2A-selective antagonist ZM241385, the A 2B-selective antagonists 3-N-propylxanthine (enprofylline) and 3-isobutyl-8-pyrrolidinoxanthine (IPDX), and the A 1-selective antagonist cyclopentyl-1,3-dipropylxanthine (CPX) were used. After the hyperoxia exposure the animals received daily intraperitoneal injections of pharmacologically relevant doses of AdoR antagonists for 5 days. Control animals received vehicle (0.1% dimethyl sulfoxide [DMSO]) alone. The animals were then killed and perfused with fluorescein-dextran. Whole-mounts of retinas from one eye were prepared and examined, whereas the retinas of the contralateral eye were embedded, sectioned, and stained for counting neovascular nuclei extending beyond the internal limiting membrane into the vitreous. RESULTS. Angiography of wholemount retinas showed reduction of neovascular tufts in animals treated with selective A 2B AdoR antagonists. Quantification of the extraretinal neovascular nuclei showed that only animals treated with XAC, enprofylline, or IPDX showed a significant reduction in retinal neovascularization. By contrast, neither CPX nor ZM241385 had an effect on neovascularization. CONCLUSIONS. The A 2B-seIective AdoR antagonists inhibited oxygen-induced retinal neovascularization in vivo and may provide a basic for developing pharmacologic therapies for the treatment of proliferative retinonathies.

AB - PURPOSE. The role of adenosine receptor (AdoR) antagonists in human retinal endothelial cell function in vitro has previously been determined. In this study, efficacy of AdoR antagonist administration in reducing retinal neovascularization was examined in a mouse pup model of oxygen-induced retinopathy. METHODS. A previously described model of oxygen-induced retinal neovascularization in newborn mouse pups was used to examine the effect of various AdoR antagonists on neovascularization. The nonselective AdoR antagonist xanthine amine congener (XAC), the A 2A-selective antagonist ZM241385, the A 2B-selective antagonists 3-N-propylxanthine (enprofylline) and 3-isobutyl-8-pyrrolidinoxanthine (IPDX), and the A 1-selective antagonist cyclopentyl-1,3-dipropylxanthine (CPX) were used. After the hyperoxia exposure the animals received daily intraperitoneal injections of pharmacologically relevant doses of AdoR antagonists for 5 days. Control animals received vehicle (0.1% dimethyl sulfoxide [DMSO]) alone. The animals were then killed and perfused with fluorescein-dextran. Whole-mounts of retinas from one eye were prepared and examined, whereas the retinas of the contralateral eye were embedded, sectioned, and stained for counting neovascular nuclei extending beyond the internal limiting membrane into the vitreous. RESULTS. Angiography of wholemount retinas showed reduction of neovascular tufts in animals treated with selective A 2B AdoR antagonists. Quantification of the extraretinal neovascular nuclei showed that only animals treated with XAC, enprofylline, or IPDX showed a significant reduction in retinal neovascularization. By contrast, neither CPX nor ZM241385 had an effect on neovascularization. CONCLUSIONS. The A 2B-seIective AdoR antagonists inhibited oxygen-induced retinal neovascularization in vivo and may provide a basic for developing pharmacologic therapies for the treatment of proliferative retinonathies.

UR - http://www.scopus.com/inward/record.url?scp=0035653641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035653641&partnerID=8YFLogxK

M3 - Article

C2 - 11726639

AN - SCOPUS:0035653641

VL - 42

SP - 3320

EP - 3324

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 13

ER -